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International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Pre-
vention, Atlanta, Georgia, United States, 19–20 July 2007
a r t i c l e i n f o
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An international meeting on Bordetella pertussis assay standardization and harmonization was held at the
Centers for Disease Control and Prevention (CDC), Atlanta, GA, 19–20 July 2007. The goal of the meeting
was to harmonize the immunoassays used for pertussis diagnostics and vaccine evaluation, as agreed
upon by academic and government researchers, regulatory authorities, vaccine manufacturers, and the
World Health Organization (WHO).
The primary objectives were (1) to provide epidemiologic, laboratory, and statistical background for
support of global harmonization; (2) to overview the current status of global epidemiology, pathogene-
sis and immunology of pertussis; (3) to develop a consensus opinion on existing gaps in understanding
standardization of pertussis assays used for serodiagnosis and vaccine evaluation; and (4) to search for a
multicenter process for addressing these priority gaps. Presentations and discussions by content experts
addressed these objectives. A prioritized list of action items to improve standardization and harmoniza-
tion of pertussis assayswas identifiedduring a groupdiscussion at the endof themeeting. Themajor items
included: (1) to identify a group that will organize, prepare, maintain, and distribute proficiency panels
and key reagents such as reference and control sera; (2) to encourage the development and identification
of one or more reference laboratories that can serve as an anchor and resource for other laboratories;
(3) to define a performance-based assay method that can serve as a reference point for evaluating lab-
oratory differences; (4) to develop guidance on quality of other reagents, e.g., pertussis toxin and other
antigens, and methods to demonstrate their suitability; (5) to establish an international working group
to harmonize the criteria to evaluate the results obtained on reference and proficiency panel sera; (6) to
create an inventory to determine the amount of appropriate andwell-characterized sera that are available
globally to be used as bridging reagents for vaccine licensure; and (7) to seek specific guidance from regu-
latory authorities regarding the expectations and requirements for the licensure of new multicomponent
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. Introduction
Pertussis (whooping cough) is a highly contagious, acute respi-
atory illness caused by the bacterial pathogen Bordetella pertussis.
espite high vaccination coverage, pertussis continues to be a
ajor cause of morbidity and mortality in the United States,
ith 25,616 and 15,632 probable or confirmed cases reported in
005 and 2006, respectively [1–5]. Among the reportable bacterial
accine-preventable diseases in the United States with univer-
al childhood vaccination, pertussis is the least well controlled
1]. Pertussis also remains a substantial public health problem in
ther developed regions, such as the European Union and Canada
6–10]. Studies suggest that there are approximately 48.5 mil-
 The findings and conclusions in this report are those of the author(s) of each
ection and do not necessarily represent the entire group of participants or the
fficial position of the Centers for Disease Control and Prevention/Agency for Toxic
ubstances andDiseaseRegistry. Thefindings and conclusions in this report havenot
een formally disseminated by the U.S. Food and Drug Administration and should
ot be construed to represent any Agency determination or policy.
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oi:10.1016/j.vaccine.2008.11.072ion annual cases of pertussis worldwide, with 295,000 deaths
11–13]. However, the total burden of pertussis is likely underes-
imated, especially among adolescents and adults, in whom typical
ertussis symptoms are often absent making diagnosis difficult
1,2,4,12–15].
The laboratory diagnosis of pertussis is challenging [16,17]. Cul-
ure is highly specific but requires a long incubation and sensitivity
an be low [16,18]. Rapid, sensitive, and specific polymerase chain
eaction (PCR) assays have been designed to detect B. pertussis
11,19–21]; however, these assays are not well standardized and
roblems have occurred with specificity, mainly during outbreaks
3,22–24]. Serologic testing with B. pertussis antigens, pertussis
oxin (PT) in particular, can be sensitive and specific, but the tests
re not widely available, have not been fully standardized and no
niversally accepted serologic correlates for protection are avail-
ble [25–28].The meeting sessions covered the following topics: global epi-
emiology of B. pertussis disease; pathogenesis and immunology
f B. pertussis; assay standardization and harmonization; sero-
iagnosis of B. pertussis; current and future B. pertussis vaccine
omposition; and issues in vaccine evaluation with perspectives
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rom regulatory authorities and vaccine manufacturers. Group dis-
ussions included serodiagnostics, vaccine evaluation, correlates of
rotection, and harmonization of assays. A list of action items was
eveloped to identify existing knowledge gaps and to coordinate
nternational efforts to standardize pertussis assays for immuno-
ogic and diagnostic use.
The meeting was opened by M. Lucia Tondella, PhD (CDC),
ollowed by Nancy Messonnier, MD (CDC), who stressed the impor-
ance of having laboratory, epidemiologic and statistical groups
orking together to facilitate and support global harmonization.
r. Messonnier also highlighted the necessity of improving pertus-
is diagnostics, pointing out that in 2007 alone, CDC experienced
umerousoccasionswhenproblemswithdiagnostics impededepi-
emiologic investigations, resulting in a substantial public health
utcry [3]. CDC’s Meningitis and Vaccine Preventable Diseases
ranch has an extensive experience working on standardization
nd harmonization of assays on a variety of organisms, and this
xperience can be brought to bear at this meeting to determine
he current status of pertussis serologic technologies in key lab-
ratories, to facilitate discussion of the key issues in pertussis
erology and to establish consensus on the action plan needed to
ddress these issues. Presentations and discussions were summa-
ized below.
. Epidemiology—current status of global B. pertussis
isease
Presenters: James D. Cherry, MD (David Geffen School of
edicine, University of California, Los Angeles) and Nicole Guiso,
hD (Institute Pasteur, Paris, France)
In theprevaccine era in theUnited States, pertussiswas adisease
ith cyclic peaks averaging every 3.3 years. The average rate of
eported cases was 157 per 100,000 population. More than 93% of
eported cases occurred in children younger than 10 years of age.
y the 1970s, pertussis was well controlled by immunization, and
nly 1000–2000 cases were reported per year; 50% of those cases
ccurred in infants. At present,more than 65% of pertussis reported
ases are in persons older than 10 years of age. Since 1984 there
as been a modest increase in reported pertussis from <1 to 9 cases
er 100,000 population. In recent years (2004–2005) the reports
ave increased considerably; however, the number of cases is still
pproximately 15-fold less than in the prevaccine era. The cycles of
eported pertussis today are essentially the same as they were in
he prevaccine era [15,29].
Examination of reported pertussis in several countries between
980 and the present found two different patterns. In some coun-
ries (Argentina, Bangladesh, Bolivia, Brazil, Cambodia, Ghana,
akistan, Peru, Sudan, Vietnam), there was a reduction in total
ases, similar to that seen in the United States between 1950 and
975. A similar pattern was also noted in the United Kingdom,
here pertussis was reasonably well controlled by vaccination in
he 1960s and early 1970s, but then concerns for vaccine safety
esulted in amarkeddecline in immunizationandpertussis became
pidemic. It was then brought under control in the early 1980s by
ncreased vaccine usage. In Italy, where vaccination was not being
onsistentlyoffereduntil theefficacy trials of1990, amarked reduc-
ion in pertussis was related to the use of diphtheria and tetanus
oxoids and acellular pertussis component (DTaP) vaccines. Success
n the control of reported pertussis in all of the above countries
ith the exception of Italy was secondary to use of 3 doses of DTwPwhole-cell vaccines) in the first year of life.
In France, because of high vaccination coverage among children
ith DTwP vaccine during the last 40 years, pertussis predomi-
antly affects children who are too young to be vaccinated and
dults who are no longer protected by vaccine or disease-induced
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mmunity [30–35]. A surveyundertaken in 1993 and1994 in a pedi-
tric hospital network demonstrated an increase in the number
f children hospitalized with pertussis suggesting the importance
f introducing booster dose(s) to prolong vaccine immunity and
educe the exposure to B. pertussis of infants too young to be immu-
ized [31]. Therefore, a fifth dose of acellular pertussis (aP) vaccine
as introduced for 11–13-year olds in 1998, followed by the intro-
uction of the so-called “cocoon strategy” in 2004. The current
accine schedule consists of primary immunization for children
ged 2, 3 and 4 months and boosters at 15–18 months, at 11–13
ears old, and for young adults and healthcare workers in contact
ith infants [36].NoDTwPvaccinehasbeencommercially available
ince 2005. The national hospital-based surveillance (RENACOQ
etwork) has not shownany resurgence of pertussis. As observed in
ther countries, cyclesof thediseasehaveoccurredevery3–5years;
owever, the number of pertussis cases in 2005 did not reach the
alues observed in the earlier peak years which could be linked to
he impact of the 11–13-year booster introduced 9 years previously
35,37].
Reported pertussis cases in Australia, Chile, Israel, Japan, Nor-
ay, and Poland have increased in recent years. In Australia, Israel,
nd Norway, the increase followed the introduction of DTaP vac-
ines. Possible reasons for the resurgence of reported pertussis are
1) greater awareness of pertussis; (2) waning of vaccine-induced
mmunity; (3) lessened potency of pertussis vaccines; (4) genetic
hanges in B. pertussis; and (5) the general availability of better
aboratory tests for the diagnosis of pertussis. Of most impor-
ance is a general greater awareness of pertussis. The availability
f better laboratory tests (PCR) and single-serum serology for diag-
osing adolescent and adult pertussis has also contributed to the
ncrease in reported cases. As evidence also suggests that in gen-
ral DTaP vaccines may have less efficacy in children than the more
otent DTwP vaccines [15,38,39], it is plausible that decreased effi-
acy or duration of protection could possibly contribute to the
utbreaks that have been seen in pre-adolescence and adoles-
ence.
Investigators in the United States and other areas of the world
ave used various laboratorymethods to diagnose pertussis in sub-
ects with prolonged cough illnesses. One of the most commonly
sed diagnostic markers is high single-serum titers to PT. Results of
hese studies suggest that about 13% of prolonged cough illnesses
re due to B. pertussis infection. However, because not all adults
ave a PT antibody response following infection, the percentage is
ikely to be higher [15,29].
In summary, B. pertussis infections in adolescents and adults are
ery common. Rates of reported pertussis may be as much as 40-
o 160-fold lower than actual illness rates, and unrecognized infec-
ions (e.g., asymptomatic or with nonspecific symptoms) are likely
o be more common than symptomatic infections. Today, symp-
omatic adolescents and adults appear to be the major sources of
nfection for nonvaccinated children.
.1. Discussion
Much of the discussion relating to epidemiology focused on the
ncrease of pertussis in recent years despite adequate or increas-
ng vaccine use in young children. In general, the most likely cause
as thought to be greater awareness of pertussis. However, data
romAustralia (presented later in themeeting) suggested that false-
ositive laboratory tests contributed to the increase in reported
ertussis in at least one setting. Discussion included the possibility
hat in some instances genetic change in the pertussis organ-
sm may have contributed to increases. In countries using DTwP,
hanges in vaccine manufacturers and even lots may have a sig-
ificant relationship to efficacy. The increase in observed pertussis
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ssociated with the introduction of acellular vaccines should be
tudied more carefully.
. Pathogenesis and immunity in pertussis
Presenter: Erik L. Hewlett, MD (University of Virginia School of
edicine, Charlottesville, Virginia)
Multiple virulence factors produced by B. pertussis are able to
isrupt the normal physiology of the host, causing the disease of
ertussis [40]. This disease consists of a localized infection of the
espiratory tract,with secondary systemiceffects resulting fromthe
ctions of several bacterial products and from the host response to
hose factors. The molecular basis for the characteristic paroxys-
al cough is not known, but is not mimicked by intravenous PT
41]. One likely role of PT is to impair the innate immune response
f the host, causing leukolymphocytosis and blocking the migra-
ion of murine macrophages [42]. Reduced expression of l-selectin
n the surface of leukocytes from infants infected with B. pertus-
is has also been demonstrated [43,44]. The leukolymphocytosis
nd several other effects of PT are mediated by the ADP-ribosyl
ransferase activity of the catalytic domain. The PT binding to its
eceptor elicits a separate set of responses, known as B-subunit
ffects. Recently it has been shown that PT B-subunit activates sig-
aling through the T-cell receptor, without any contribution from
DP-ribosylation [45]. Similarly, PT and an enzymatically inactive
non-ADP-ribosylating) mutant stimulate cytokine production and
endritic cell maturation [46].
Evidence indicates that multiple virulence factors from B. per-
ussis have immunomodulatory effects. In several instances the
ffects appear to be antagonistic to one another. For example, it
as been shown that filamentous hemagglutinin (FHA) is both
ro-inflammatory and able to induce apoptosis in macrophages
47]. Similarly, adenylate cyclase toxin (ACT), which is known for
ts inhibitory effects and cytotoxicity on neutrophils and other
hagocytic cells [48–50] also has pro-inflammatory effects, induc-
ng IL-6 from respiratory epithelial cells [51] and cyclooxygenase-2
Cox-2) in cells expressing the integrin, CD11b/CD18 [52]. The dis-
ase process of pertussis appears to be multifactorial, rather than
he function of a single toxin/virulence factor. Therefore, the ideal
mmunologic response fromthehost consists of antibodiesdirected
gainst multiple virulence factors, resulting in inhibition of bac-
erial adherence, neutralization of the actions of the toxins and
learance of the infecting organisms. In addition, a cell-mediated
omponent in the host response to immunization and infection
as been studied, but the relevant target antigen(s) to which this
ellular response is directed and the contribution that it makes to
acterial clearance are unknown [53–55].
Several major issues in pertussis pathogenesis remain unre-
olved.Despite thenumerousknownbiological effects of individual
irulence factors, especially in vitro, the in vivo target tissue(s) of
hese molecules and the mechanism by which the characteristic
ough is generated aremysteries. Themolecular details of howBvg,
he two-component regulatory system, controls production of the
irulence factors are not known. In summary, pertussis is a multi-
omponent disease, which requires more than a simple approach
o its recognition, treatment and control. Recent analyses of the
ffects of known toxins and other virulence factors on the immune
ystemhave revealed that they are oftenmultifunctional: cytotoxic,
timulatory, inhibitory, pro- and anti-inflammatory..1. Discussion
Much of the discussion focused on the potential neurophysi-
logic effects of the multiple virulence factors; animal modeling,
ncluding newmethods of infection through inhalation techniques;
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nd novel imaging analysis that could help in understanding the
athogenesis of pertussis in humans. Recent research studies have
hown presence of B. pertussis DNA from clinical specimens of
hildren several months after infection. The possibility that the
emaining DNA could be triggering the cough by an unrecognized
echanism was speculated.
. Why are standardization and harmonization of B.
ertussis assays necessary?
Presenter: Kathryn M. Edwards, MD (Vanderbilt Medical Center,
ashville, Tennessee)
Standardization and harmonization are necessary for several
easons: to assess the immunogenicity of new pertussis vaccines
r new combination vaccines that include pertussis antigens, to
ompare the serologic responses to these new vaccines with those
valuated in earlier vaccine efficacy studies for the purposes of
accine licensure, to establish serologic criteria for the clinical diag-
osis ofpertussisdisease, and toconduct seroepidemiologic studies
o assess the circulation patterns of pertussis in the community.
Multiple aPvaccineswere licensed foruse in infants, adolescents
nd adults [1,2,56]. Combination vaccines incorporating various
ntigens into a single injectionhavebeendesigned. These combina-
ion vaccines may be associated with reduced serologic responses
o one or more vaccine antigens. Therefore, antibody titers induced
y these products must be compared with those seen after the sep-
rate administration of the individual vaccines before combination
accines can be considered for licensure.
Safety and immunogenicity of 13 aP and two DTwP vaccines
ave been assessed in a single large clinical trial [57]. Although the
rial evaluated different pertussis antigens administered in vari-
us concentrations, all the 15 vaccines were found to be safe and
mmunogenic. Several of these vaccines were then evaluated in
fficacy trials in the European Union and Africa and were found
o be efficacious in preventing culture-confirmed pertussis. Since
lacebo-controlled efficacy trials would now be considered uneth-
cal, new vaccines must be evaluated by comparisons with the
mmunogenicity data of the vaccines evaluated in earlier efficacy
rials. Thus, the need for standardized assays is critical.
Standardized serologic assays are also needed to diagnose per-
ussis disease, particularly in adolescents and adults. A study was
onducted to determine population-based antibody levels to three
ertussis antigens, PT, FHA, and fimbrial proteins (FIM), for the pur-
ose of establishing diagnostic cutoff points in adolescents and
dults in the United States [58]. Enzyme-linked immunosorbent
ssays (ELISAs) were performed on sera from more than 6000 US
esidents aged 6–49 years. Quantifiable (>20 ELISA units [EU]/ml)
nti-FHA and anti-FIM IgG antibodies were common but quan-
ifiable anti-PT IgG antibodies were less frequent. An anti-PT IgG
evel of ≥94 EU was proposed as the diagnostic cutoff point in
ubjects 10 years of age and older. Application of this cutoff point
o culture-confirmed illness yielded a high diagnostic sensitivity
80%) and specificity (93%). Anti-PT IgG assays with a single serum
ample appeared to be useful for identification of recent B. per-
ussis infection in adolescents and adults. However, these assays
ust be standardized to remain useful in the diagnosis of pertus-
is.
Finally, standardized serologic methods for B. pertussis are
eeded to assess epidemiologic trends in pertussis disease in the
opulation. This is particularly relevant with the universal recom-
endations for adolescent and adult pertussis vaccine in many
eveloped countries. How universal vaccination will affect disease
urden in the various age groups remains to bedetermined. In addi-
ion, comparisons of seroepidemiologic results fromone country to
nother are dependent on standardized assays.
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. B. pertussis multilaboratory serologic studies: designs,
tatus and outcomes
Presenters: Bruce D. Meade, PhD (Meade Biologics LLC, Hills-
orough, NC), Dorothy Xing, PhD (National Institute for Biological
tandards and Control (NIBSC), Potters Bar, UK) and Anna
iammanco, PhD (Department of Hygiene and Microbiology, Uni-
ersity of Palermo, Italy)
Important insightonstrategies for international standardization
f pertussis immunoassays is provided by the results of an interna-
ional collaborative study performed in 1995 [59]. In that study, 32
articipating laboratories were asked to quantify specific antibody
oPT, FHA, pertactin (PRN), and FIM in apanel of 21blinded samples
y using those ELISAs routinely performed in that laboratory. The
aboratories employed a variety of procedures, antigens, conjugates
nd other reagents, and calculation methods. Results indicated an
verall consistency among the laboratories. A reasonable quantita-
ive agreementwas achieved among the19 laboratorieswith assays
alibrated using the US reference pertussis antisera. This agree-
ent demonstrated that use of a common reference serum had
een successful at harmonizing results. To promote a higher level
f international standardization of pertussis immunoassays, the
ighest priority recommendations would be to improve the avail-
bility of reference reagents and methods, including international
eference sera, a proficiency panel of well-characterized sera, and
ell-characterized antigens.
In recent years, significant progress in the preparation and stan-
ardization of international reference sera has been made. The
HO collaborative study, “Evaluation of proposed international
eference preparations for pertussis antiserum (human),”was a
ulticenter collaboration between NIBSC, UK; the Center for Bio-
ogics Evaluation and Research (CBER) at the Food and Drug
dministration (FDA), US; the Institut für Infektiologie (IFI), Ger-
any; and a number of international participants. Reference sera
rom the United States (US reference pertussis antiserum [human]
ot 3 and lot 4 for IgG-antibodies and lot 5 for IgA-antibodies) were
repared by FDA, CBERmore than 10 years ago, and since then have
een commonly used as reference standards for pertussis sero-
ogic assays [58–63]. Currently, only limited quantities of these sera
emain. With an increasing number of vaccine and diagnostic stud-
es, more widely available international standard preparation(s)
re needed. The WHO Ad Hoc Pertussis Working Group recom-
ended the preparation and standardization of an international
uman reference antiserumtopertussis antigens to replace the cur-
ent widely used CBER preparations before the supply is exhausted
64]. It was agreed that as far as possible, continuity with the exist-
ng CBER reference preparations should be maintained. These new
nternational reference materials were intended for the following
ses: (1) vaccine studies of products in current distribution, as well
s those under development; (2) studies of serologic responses to
nfection; (3) epidemiologic surveillance; (4) future assessment of
ntibodies to other antigens apart from PT, FHA and PRN; and (5)
valuation of new generation vaccines.
Serum pools were kindly donated by Dr. Wirsing von König,
FI, Krefeld, Germany. They were prepared after recalcification of
lasma samples selected from a blood bank during a pertussis
utbreak in Germany. These sera were then lyophilized at NIBSC,
esulting in four batches of freeze-dried preparations of 7800
mpoules of higher titer and 14,500 ampoules of lower titer IgG-
nti-PT. Preliminary assessment of the freeze-dried materials in
IBSC showed that in comparisonwith thematerials before freeze-
rying, all freeze-dried material maintained their original ELISA
inding activities. Furthermore, comparison of the candidatemate-
ials with the US reference sera showed that the dose–response
ines did not deviate significantly from parallelism.
a
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An international collaborative study to evaluate the candidate
reparations was initiated in March 2007. The aims of the study
ere to (1) characterize candidate international reference prepa-
ations for pertussis antiserum (human); (2) compare candidate
eferences with the US reference preparations, lots 3, 4, and 5;
3) compare candidate reference preparations with other avail-
ble reference preparations, e.g., in-house preparations; and (4)
efine unitage for the candidate preparations for anti-PT, anti-FHA
nd anti-PRN, maintaining continuity with widely used reference
reparations.
Samples provided to the participants were the four candidate
eference preparations: the three US reference sera plus a nega-
ive control serum. All participants were quested to (1) carry out
hree independent assays for IgG anti-PT, FHA and PRN by ELISAs;
2) use their own methodology, reagents and calculation methods;
nd (3) include their in-house references and controls. Participants
ere also encouraged to perform other assays that could be of
nterest, e.g., IgG anti-FIM 2/3, IgA antibodies to the antigens, PT-
eutralizing antibodies (CHO-cell assay). A total of 23 laboratories
orldwide participated in this study, including 10 from Europe, 8
rom North America, 2 from South America and 1 laboratory from
achofAsia andAustralia. All participantswere requested to submit
heir raw results to NIBSC,where the statistical analysiswill be per-
ormed. A study report will be submitted to the Expert Committee
n Biological Standardization (ECBS) of WHO.
Another multilaboratory effort to standardize pertussis sero-
ogic assays was the European Sero-Epidemiology Network (ESEN)
roject, coordinated by the Health Protection Agency (HPA), Com-
unicable Disease Surveillance Center (CDSC), London [62,65]. The
im of the ESEN project was to coordinate and harmonize sero-
ogic surveillance for a variety of infections in Europe. Age-stratified
erum banks of a recommended sample size of 3300 individuals
ere collected by each participant country and one laboratory was
elected to serve as a reference laboratory for each disease. All lab-
ratories tested sera from their own country plus a shared panel of
pproximately 150 serum samples [62].
The standardization process allowed a comparison of national
erosurveys for pertussis [62]. Because of the difficulty with stan-
ardization of cell extracts, the ESEN project emphasized purified
ntigens, focusing on IgG anti-PT assays because of the higher
ensitivity and specificity for serodiagnosis [62]. Since most indi-
iduals had been exposed to pertussis vaccine or infection, the
tudy focused on an estimation of the incidence of recent infec-
ions, as defined by the presence of IgG anti-PT antibodies above
efined thresholds [61]. To accomplish this, quantitative assays
ere required and standardization efforts were based on analyt-
cal performance in the assay range near the diagnostic thresholds.
n conclusion, the ESEN project demonstrated that standardization
f pertussis IgG anti-PT assay was possible [62,66].
. Serodiagnosis of B. pertussis in different countries
Presenters: C.H. Wirsing von König, MD (Institute fur Hygiene
nd Labormedizin, Krefeld, Germany), Nicole Guiso, PhD (Institute
asteur, Paris, France), Linda Han, MD, MPH (Bureau of Laboratory
ciences, Department of Public Health, Boston, Massachusetts, US),
nd LindaHueston,MS (Centre for Infectious Diseases andMicrobi-
logy (CIDM), Institute of Clinical Pathology and Medical Research
ICPMR), Westmead, Australia)
Appropriate application of a diagnostic laboratory test requires
n understanding of the test as well as knowledge of the patient.
elevant criteria for the test include test format; specificity and
ensitivity; and reference systems. Clinical interpretation of a test
esult concerningB. pertussis infection also requires an understand-
ng of (1) the distinction between primary and secondary infection;
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2) the differential diagnoses, including other agents; (3) the kinet-
cs of immune responses to infection; and (4) an understanding of
he information provided by the test beyond that provided by the
linical history alone. The performance of laboratory tests can be
isplayed by cutoff values as shown in a reporter–operator charac-
eristics (ROCs) curve, aswell as by positive and negative predictive
alues. The differential diagnosis for B. pertussis as an agent of
rolonged cough includes infectious agents such as adenovirus,
espiratory syncytial virus, rhinovirus, human parainfluenzavirus,
nfluenzavirus A and B, Mycoplasma pneumoniae, human metap-
eumovirus, and human coronavirus.
Several alternate approaches have been used for serodiagnosis.
hen paired sera were used, one study defined a case if there was
00% or more increase in antibody concentration or 50% or more
ecrease in antibody concentration. For single-sample serology,
arious cutoff-values have been proposed, such as >∼125EU/ml
gG-anti-PT in the Netherlands; and >100EU/ml IgG-anti-PT or
gG-anti-PT>50EU/ml and IgA-anti-FHA>50 in Germany. In most
iagnostic laboratories, a so-called “grey-zone” is defined for sera
hat are positive and above a specified threshold but between the
iagnostic cutoffs. This “grey-zone” is set in the Netherlands and
weden to 20EU/ml of IgG-anti-PT.
The sensitivity and specificity of single-sample serologic assays
ave been determined. One study was done in a population of chil-
ren 0–11 years of age, mostly nonvaccinated (Germany), using a
ut-off of ∼50EU/ml (95th percentile of population). With a speci-
city of 95%, a sensitivity of 67% was found, which increased to 82%
hen IgA-anti-FHA was added [67]. Another study was done with-
ut age limit in amostly vaccinated population (Netherlands) using
cutoff of ∼125EU/ml (99th percentile of population). The study
ound a sensitivity of 76.4%, whereas a cutoff ∼62EU/ml (∼95th
ercentile of population) had a sensitivity of 88.8% [61].
A recent German study evaluated 243 persons in hospital
epartments, pediatrician’s offices, and child-care facilities, who
eceived one injection of aP vaccines. After informed consent, blood
as sampled before vaccination, and 1 month, 1 year, 2 years, 3
ears and 4 years after vaccination. IgG- and IgA-antibodies to PT,
HA and IgG-anti-PRN were measured. In this population, when
he distribution of IgG anti-PT levels prior to immunization was
xamined, the 95th percentile was 47EU/ml, the 98th percentile
as 103EU/ml, and the 99th percentile was 163EU/ml.
Applying a cutoff of 125EU/ml to a seroepidemiologic study in
population of persons aged 20 to >65 years in various countries
n the European Union resulted in the following percentage of the
ohort showingvalues above the cutoff:Netherlands (1.4%), Finland
1.5%), Germany (former GDR) (1.7%), France (2.3%), Germany (for-
er FRG) (3.0%), UK (5.0%), and Italy (6.5%) [66]. Seroepidemiologic
tudies can also demonstrate the cyclic nature of B. pertussis infec-
ions. InGermany, apopulationof 18–60-year-oldblooddonorswas
creened in different years. The percentage of this cohort with IgG-
nti-PT≥100EU/ml was as follows: 4/600 (0.7%) in 2002; 6/1500
0.4%) in 2003; and 70/2000 (3.5%) in 2005.
For a diagnostic laboratory, it is important to definehow the cus-
omer will use the serologic information, specifically if it is used for
linical decisions and patient management or if it is used for epi-
emiologic studies. Similarly, clarity is needed regarding whether
he definition should include all infections, symptomatic infec-
ions, infections with medical resource use, or severe infections.
iagnostic serology is also strongly influenced by the time when
atients seek medical attention relative to onset of symptoms. In
ermanstudiesperformedamongpersonswithPCR-positive cases,
he median number of days of coughing before seeking medical
ttention was found to be 7.8 days for schoolchildren, aged 7–12
ears, 12.5 days for adolescents, aged 12–18 years, and 17.3 days for
dults, aged 18–81 years.
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In France, serologic testing is performed for epidemiologic stud-
es and surveillance. Serology consists of measurement of IgG
nti-PT antibody titers using the reference ELISA and purified PT
rovided by the manufacturers [68]. A positive case is defined by
ither a twofold change in the titers between two serum samples
btained at a 1-month interval or a titer >100EU/ml in a sin-
le serum sample, only if the serum is collected after more than
weeks of cough and 3 years after a vaccine booster. In some
rench laboratories, an “in house” Western blot assay using puri-
ed PT, as well as various commercial tests have been used for
outine diagnoses. These assays are not validated and have also
een responsible for false-negative or false-positive results. For this
eason, microbiologists have preferred real-time PCR for routine
iagnoses. Serology based on measurement of anti-PT titers may
e less useful in the future, since children, adolescents and now
dults are vaccinated with aP vaccines containing PT. The propor-
ion of laboratory tests performed to diagnose pertussis in France
as changed over the years, according to the RENACOQ database
37]. In 1997, 84% of pertussis cases were diagnosed by culture, 50%
y PCR and 23% by serology, whereas in 2005; 67% of cases were
iagnosed by culture, 90% by PCR and only 1% by serology.
In the United States, the Massachusetts State Laboratory Insti-
ute has been using a single-serum anti-PT IgG EIA on patient
amples since 1987. Other versions of the current assay have been
sed in the past, including measurements of IgA and IgM to PT, IgG
o FHA, and anti-PT IgG in paired sera. Ultimately, all these other
ssays were discontinued when data indicated that they did not
ontributemuchadditional informationbeyond that obtained from
he single anti-PT IgG alone.
Plates are coated with commercially prepared PT. Standards are
erived from pools of positive patient samples and are calibrated
gainst the US reference lot 3. A concentration (g/ml) is assigned,
alculated from a five-point standard dilution curve. The cutoff
oint for positivity was established on 100 adults, including blood
onors and healthy volunteerswith anti-PT IgG levels ranging from
.1 to 15g/ml [63]. A cutoff point was chosen based on the 99%
pper tolerance limit, such that there is 95% confidence that 99%
f the population falls below the cutoff. The cutoff point was set
t 20g/ml, which is equivalent to 200 CBER units per ml. This
s actually quite high relative to what other groups have chosen
58,61].
Clinicians are asked to order a serologic assay only for patients
ho are older than 11 years of age and only when coughing has
een present for more than 14 days. Specimen volumes have been
ncreasing steadily over the last 15 years, so that in 2006,more than
000specimenswere tested. Seropositivityhasbeen fairly constant
t approximately 10% of the submitted samples.
Many of the challenges associated with the assay arise from
anipulations needed to produce a quantitative test result. It may
ake sense, at least in Massachusetts, to consider some modifica-
ionof the assay tomake itmorequalitative, simple, and robust, and
ble to be performed consistently and accurately with less effort
han is currently expended.
At least two knowledge gaps prevent wider application of
he assay. First, the impact on assay results of adolescents and
dults having recently received tetanus toxoid, reduced diphthe-
ia toxoid and acellular pertussis (Tdap) vaccination is not fully
nderstood. The Massachusetts Immunizations Program contacts
very seropositive patient and asks about recent vaccination his-
ory. In the last 2 years, since Tdap has been available, only two
eropositive patients with recent Tdap vaccination have been iden-
ified. One person was vaccinated the day before blood was drawn
or serology, so the antibodies detected were unlikely to have been
ue to vaccine. In Massachusetts, Tdap-associated IgG may be less
f a problem than was originally anticipated. Possibly, post-Tdap
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mmunization IgG levels do not frequently exceed the relatively
igh assay cutoff value. Alternatively, clinicians may not be sub-
itting samples from recent vaccine recipients, recognizing that
hose individuals are likely to be protected from disease.
A second knowledge gap is the uncertain applicability of IgG
IA results to children younger than 11 years of age. Results are
onsidered uninterpretable for that age group, because of the pos-
ible presence of vaccine-associated antibody. Massachusetts State
aboratory Institute data on seropositivity by age demonstrate a
eak in seropositivity among adolescents and young adults, and
lso a peak at 5–6 years of age. Admittedly, no clinical informa-
ion is available for the 5–6-year-old patients because they are not
onsidered to be pertussis case-patients and are not investigated.
n addition, their vaccination status is unknown. Nevertheless, the
eak in seropositivity that occurs at this age may correspond to the
fth dose of DTaP. Interestingly, the peak is not very wide, span-
ing only 2–3 years, so the application of the assay could likely be
xtended down to some ages less than 11 years.
Australiahas a16-year experienceofusing commercial serologic
its for the routine diagnosis of pertussis. IgA has been used rather
han IgGkitsbecause IgA isbelieved tobeshort-lived (12–14weeks)
n comparison to IgG (26–52 weeks), and, in children at least, IgA
s not produced in response to the vaccine.
Unusually large numbers of pertussis IgA-positive tests were
eported to public health authorities during 2006. At the time, only
wo IgA commercial serologic tests were used, ELISA kit 1 (82% of
aboratories) and ELISA kit 2 (15% of laboratories). This prompted
widespread evaluation, comparing various commercial available
LISA kits with complement fixation (CF), IgA immunofluoresence
IF) and IgA Western blot (WB) kits. Ninety healthy adults with no
linical history of respiratory illness in the preceding 12 weeks and
egative by CF, IF and WB formed the negative group for the eval-
ation. The positive group consisted of 27 children and adults with
clinical history of pertussis of less than 6 weeks’ duration and
ositive by CF, IF and WB. The respective antigens, sensitivity and
pecificity of each commercial IgA ELISA kit were as follows: (1) kit
, whole cell, 66.7%, 86.7%; (2) kit 2, FHA&PT, 59.3%, 94.4%; (3) kit
, FHA&PT, 74.1%, 98.9%; (4) kit 4, FHA&PT, 77.8%, 97.8%; (5) kit 5,
HA&PT, 77.8%, 97.8%; (6) kit 6, FHA&PT, 37.0%, 92.2%; (7) kit 7, PT,
3.3%, 90.0%; (8) kit 8, FHA&PT, 59.3%, 87.8%; (9) kit 9, FHA&PT,
3.0%, 85.6%; (10) kit 10, FHA&PT, 85.2%, 83.3%; and (11) kit 11,
HA&PT, 66.7%, 76.7%. These results demonstrate a wide variability
mong the commercial tests evaluated.
In 2006, CIDMS laboratory tested 1547 serum samples for per-
ussis IgA using the ELISA kit 1. Following the evaluation of various
ommercial tests, over 90% of these samples were retested and
3% were found to be false-positives. The false-positive specimens
eacted with the FHA antigen band only, suggesting that PT would
e a better choice for an ELISA antigen. However, the only kit that
sed PT as an antigen performed poorly, which emphasizes the
eed for better standardization. In addition, a group of 70 negative
amples was tested by the ESEN IgG ELISA [62] using a 100EU/ml
utoff; 20 samples had IgG levels >100 units, which would have
een interpreted as evidence of recent infection when clearly these
ndividuals were not symptomatic. This highlights the need for
aution in determining a cutoff for recent infection in adults, par-
icularly in highly vaccinated populations.
In general, diagnostic laboratories prefer commercially available
ssays. Two studies so far have evaluated selected commercially
vailable ELISAs for B. pertussis serology: Kösters et al. used paired
era from 20 patients (children), sera from 15 vaccinees, 7 inter-
aboratory comparison samples, and 4 reference preparations [69].
chellekens et al. used paired sera from 41 PCR-positive patients
median age 3 years) and 65 control patients with respiratory
ymptoms (median age 30 years) [70]. Another study with various
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urrentlyexisting serologic tests is ongoingandresults areexpected
o be available in early 2009.
In summary, B. pertussis serodiagnosis still suffers from many
nsolved problems, such as that diagnostic testing is performed
n immunologically non-naive populations with antigens that are
omponents of aP vaccines. Generally an anamnestic immune
esponse develops more rapidly than symptoms, and immune
esponses to vaccine antigens cannot be distinguished from
esponse to infection. Problems also exist with serodiagnosis of B.
arapertussis infections. Serologic interpretation requires knowl-
dge of pertussis immunization, information not typically known
y the testing laboratory. Reliable, standardized ELISA systems are
ot commercially available at this time. Additionally, the clini-
al course appears to differ between primary and non-primary
nfections. For most subjects, clinical case definitions for pertus-
is remain nonspecific. There are currently no suitable serologic
ests for recently vaccinated patients, since tests based on nonvac-
ine antigens have not been satisfactory for diagnosis. Finally,when
sing single-sample serology, population-based cut-offs will need
e-verification after any change made in a vaccination schedule.
.1. Discussion
Discussion focused on the use of antigens not present in vac-
ines for serologic diagnosis of pertussis. Cherry et al. [71] showed
hat patientswith vaccine failure responded poorly to the ACT anti-
en, suggestingan induced tolerancedue to thephenomenoncalled
original antigenic sin.” In this phenomenon, vaccinated patients
espond to antigens that they have been primed with and do
ot respond to new antigens (e.g., ACT) associated with infection.
herefore, it was suggested that nonvaccine antigens may not be as
ood as PT for serologic diagnosis of pertussis in vaccinated pop-
lations. Other points of discussion included the potential use of
everse vaccinology approach to identify newantigen candidates to
e used in serologic diagnostics and lack of specificity of other anti-
ens other than PT, such as FHA and ACT. The lack of sensitivity and
pecificity of commercial tests currently available worldwide was
roadly discussed. It was pointed out that one commercial IgG and
gAanti-PT test available in theUnited States has been standardized
o provide adequate sensitivity and specificity for the diagnosis of
ertussis in persons older than 10 years of age.
. Correlates of protection
Presenter: James D. Cherry
In studies of whole-cell pertussis vaccines, agglutinin titers of
:320 or greaterwere found to beprotective against pertussiswhen
hildren were exposed within the household [72]. Agglutinating
ntibodieswere thought to be primarily directed against the agglu-
inogens FIM-2/3, PRN and lipopolysaccharide.
Only two of the nine aP vaccines efficacy trials conducted during
he 1980s and 1990s were done in such a way that data relating to
erologic correlates could be developed. These trials were centered
n Erlangen, Germany, and Stockholm, Sweden [27,28,73,74]. To
etermine serologic correlates, antibody titers to specific antigens
ere determined at the time of exposure. Both studies indicated
hat PRN was most important in protection and that antibody to
IM was next most important. Also noted in both studies was an
pparent antagonism between antibody to PT and FIM. In clinical
rials in which children with both mild and severe disease were
ncluded in the analyses, efficacy jumped considerably for vaccines
hat contained PRN as well as PT and FHA when compared with
T and PT/FHA vaccines. In the Erlangen trial, the imputed titers
t the time of exposure in 6 DTP and 11 DTaP vaccine failures were
xamined. In the majority of the failures, subjects had high levels
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f antibody to PRN, which is difficult to explain in relation to the
verall data on serologic correlates. This indicates that there is
uch yet to be learned about serologic correlates. Of interest is
he fact that when a DTwP vaccine (Evans vaccine) was compared
ith a two-component DTaP vaccine, a three-component DTaP
accine and a five-component DTaP vaccine, the greatest efficacy
as noted with the DTwP vaccine. This vaccine elicited minimal
ntibody responses to PT and FHA (10 and 34EU/ml, respectively)
nd high values to PRN and FIM (150 and 677EU/ml, respectively).
.1. Discussion
Discussion centered on diagnosing pertussis serologically using
ntigens contained in the vaccines and antigens not contained in
he vaccines. Although still controversial, if acute-phase serum is
ollected early, titer increases against both vaccine antigens and
onvaccine antigens are useful for diagnosis. Further discussion
elated to cell-mediated responses associated with infection, use
f animal models in studies of infection and consideration of addi-
ional antigens that might be included in vaccines.
. The composition of B. pertussis vaccine with
onsiderations for the future
Presenter: John B. Robbins, MD (National Institutes of Health,
ethesda, Maryland, US)
Dr. Robbins presented evidence supporting the hypothesis,
ased on the classic article by Pittman [75], that an inactivated and
mmunogenic pertussis toxoid (PTox) is both essential and suffi-
ient for a pertussis vaccine [76]. Furthermore, he discussed data
uggesting that multicomponent pertussis vaccines include non-
rotective antigens [77,78] andmaybemoredifficult to standardize
79].
US pertussis cases reported to CDC have increased despite a
igh immunization rate among infants and children [1–3,5,56].
ooster doses, starting in adolescence and offered every 10 years,
ill maintain a high level of immunity in the population, and Dr.
obbins recommended that a genetically inactivated toxin should
eplace the chemically inactivated toxoids for mass immunization
f infants, adolescents and adults [80,81].
With respect to the goals of the meeting, the importance of
ssays to measure serum PT IgG was emphasized because PT IgG
s the only reliable assay for serologic diagnosis of pertussis after
he acute phase of pertussis has passed [67,68], and because the
oncentration of vaccine-induced IgG anti-PT correlated with the
fficacy of monocomponent PTox [82]. The correlation indicates
hat the level of IgG anti-PT may predict the efficacy of aP vaccines
82].
.1. Discussion
Anumber of participants raised questions related to the hypoth-
sis that PTox alone is sufficient for a pertussis vaccine. It was
entioned that the study supporting the hypotheses did not
nclude serology. Other studies, including serologic ones, showed
vidence that addition of FHA in the vaccine provides some protec-
ion against infection. Data (not included in this report) based on
xtensive investigations in Sweden and presented at themeeting in
supplemental presentation by Rose-Marie Carlsson, MD, Swedish
nstitute for Infectious Disease and Control, contradicted many of
he conclusions presented in this session. Some participants also
uestioned the appropriateness of the analogy between diphtheria
nd PToxs. The presentation on pathogenesis and immunity as well
s the presentation on correlates of protection at this meeting are
lso at variance with the hypothesis that PTox alone is sufficient for
d
c
t
d
h27 (2009) 803–814 809
pertussis vaccine. The discussion was cut short to allow adequate
ime for consideration of issues related to assay standardization,
he main focus of the meeting.
. Vaccine evaluation based on B. pertussis
mmunogenicity data (Discussion)
Some conclusions previously reached by a WHO-convened
orking group on the clinical evaluation of new aP vaccines served
s an introduction to discussion. One such conclusion was that
dditional placebo-controlled protective efficacy studies were not
easible since withholding pertussis vaccine was no longer a possi-
ility. Relativeefficacy studiesof adequate sizeandstatistical power
lso seemed unlikely. The approval of new aP vaccines would have
o rely on comparative immunogenicity data.
All the aP-containing vaccines that have been licensed thus far
n the United States and European Union incorporate the same per-
ussis antigens made by manufacturer-specific processes as were
ncluded in at least one of the successful vaccine efficacy trials
n infants. Therefore, immunogenicity data have been used to link
he demonstration of efficacy for the tested aP vaccine to the new
P vaccine even when the total antigen compositions of the two
accines differ.
Comparisons of immune responses between the new and refer-
nce aP-containing vaccines raise several difficult questions. For
xample, with no identified immunologic correlates of protec-
ion against pertussis, it is not known which antigen(s) elicits
mmune responses that are important for prevention of clinically
pparent infection. It is also not known whether the primary com-
arison should be in terms of percentages with postvaccination
iters above the assay cutoff, on seroconversion rates (which are
pen to various definitions) or to geometric mean antibody titers.
hichever immunologic parameter is chosen for the primary com-
arison, it is difficult to decide what might constitute a clinically
mportant difference. In addition, the predefined criteria for non-
nferiority might be met for one or more, but not all immunologic
arameters, with unknown implications for protection. Because
f these uncertainties, the overall judgment of the likely protec-
ive efficacy of an aP-containing vaccine should take into account
ll aspects of immune responses. Thus the immunogenicity data
hould be described in terms of percentages of subjects reaching
ssay cutoffs, percentages achieving fourfold increments in anti-
ody concentrations (or a similar definition of seroconversion),
eometric mean antibody titers and reverse cumulative distribu-
ions.
The uncertainty regarding the predictive value of these
mmunologic comparisons supports the importance of postlicen-
ure surveillanceprograms toassess theeffectivenessof aPvaccines
gainst pertussis disease. However, it is very unlikely that vaccine-
pecific estimates of effectiveness could be generated, since this
ould require data from a region or country in which the vaccines
sed all contain the same aP antigens from the same manufacturer.
ecause of the complexities of such programs and the infrastruc-
ure needed to generate reliable data on disease, such data are
ost likely to come from surveillance conducted by public health
gencies.
In the future, new aP-containing vaccines might include the
ame range of aP antigens previously shown to be efficacious, but
omeorall of thesemaybemadebyadifferentmanufacturerand/or
y adifferent process.NewaP-containingvaccines could alsohave a
ifferent compositionof pertussis antigens (in type and/or amount)
ompared with vaccines that were previously evaluated for protec-
ive efficacy. There is no agreed regulatory position on the minimal
ata that would be required to support approval of these products;
owever, practical limitations point to the need to consider how
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mmunogenicity data could be best used to provide reassurance
egarding likely efficacy.
If a new aP-containing vaccine contains only antigens that were
ncluded in at least one vaccine evaluated in previous protec-
ive efficacy studies then immune responses could be compared
etween the new vaccine and an approved vaccine that has the
ost similar aP antigen content. If the new aP-containing vaccine
ontains fewer antigens, different amounts of antigens and/or addi-
ional antigens as those in vaccines previously shown to provide
rotective efficacy there is a need for a careful justification of all the
ifferences between the new and past efficacious vaccines, which
ould likely have to be based on nonclinical studies. In particular,
he response to the PT component should be fully assessed for effi-
acy in animal models and by estimating the functional antibody
o PT (for example, by using the CHO cell neutralization assay). The
urity, integrity and functional activity of all antigens should be
ssessed by physical–chemical evaluation, measurement of resid-
al toxicity (if applicable) andassessmentof immunogenicitybased
n binding and functional assays and protective effects in relevant
0. Vaccine evaluation: perspectives from regulatory
gencies, and vaccine manufacturers
Presenters: Drusilla Burns, PhD (Center for Biologics Evaluation
nd Research (CBER), Food and Drug Administration, Bethesda,
aryland, US), Dorothy Xing, PhD (National Institute for Biological
tandards andControl (NIBSC), Potters Bar, UK), Jan T. Poolman, PhD
Bacterial Vaccine R&D, GlaxoSmithKline Biologicals, Rixensart,
elgium) and StephenW.Hildreth, PhD (sanofi pasteur, Swiftwater,
ennsylvania)
0.1. A view from the regulatory authorities: FDA, US
To begin with a brief overview of pertussis vaccine evaluation
n the United States, aP vaccines were first licensed for toddlers in
991, for infants in 1996, and for adults and adolescents in 2005.
erologic responses to aP vaccination have been used as a measure
f lot-to-lot clinical consistency, to bridge populations, and to eval-
ate booster immunizations, new combinations and concomitant
accination. Relevant parametersmeasured have included geomet-
ic mean concentrations as well as percentage of responders. In
ddition, reverse cumulative distribution curves have proved to be
n informative way to display serologic response data.
0.2. A view from the regulatory authorities: NIBSC, UK
The composition and formulation of aP vaccines vary widely
etween manufacturers and products, and no globally accepted
eference preparations and release criteria have been established;
hus, current reference materials and release criteria are product-
pecific. This causes difficulty in standardization of the laboratory
ests for control of these vaccines. The basis of current regulatory
pproaches is to demonstrate that newly manufactured lots are
omparable either to lots shown to have acceptable clinical trial
erformance or to lots considered equivalent to these clinical trial
ots.
Current routine control tests for aP vaccines include characteri-
ation of antigens, assay of immunogenicity, and assay of residual
T bioactivity by the histamine sensitization test and identity test-
ng of antigenic components. A modified intracerebral challenge
ssay (MICA, modified Kendrick test) has been used in Japan, Korea
nd China as the potency assay for release with a specification
4unit/dose; vaccines regulated using this approach have been
hown to be effective in controlling pertussis. In other countries, no
ationally defined official potency test has been used at present. An
t
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mmunogenicity test has been used for monitoring consistency of
roduction in routine control procedures with comparison with a
linical trial lot (or equivalent). However, the criteria for evaluating
quivalency must be defined and no defined common specification
as been set.
Recent evidence suggests that both antibody and cell-mediated
mmunity contribute to the protective process to a variable extent.
ollowing the decision made at the WHO Ad Hoc Working Group
eeting (1998, NIBSC, UK), international collaborative studies on
rotection models for aP vaccines were initiated in 1999, and the
utcome of these studies was discussed in subsequent WHO work-
ng group meetings. The harmonized procedure for the intranasal
hallenge assay (INCA), defined in 2003, has been shown to be
ffective for monitoring the activity of different vaccines and to be
ransferable between laboratories [64,83,84]. Future work on opti-
izing experimental conditions to allow calculation of a relative
otency is needed and a reference vaccine needs to be agreed upon.
his model should be useful for development and characterization
f new products or formulations, performing preclinical evaluation
r stability and lot consistency monitoring.
The current safety tests for aP vaccines include assays for resid-
al active PT and reversibility of detoxification based on histamine
ensitization activity, an endotoxin assay and a general toxicity
est. The absence of other toxins at significant levels (heat-labile
oxin, ACT, tracheal cytotoxin) has been controlled through process
alidation. Problems associated with the histamine sensitization
est include variation in test performance among laboratories and
he absence of an internationally defined acceptance criterion for
he assay. The influence of significant interactions between PT and
ther vaccine components over histamine sensitization assay is
nknown. The assay could be improved by (1) defining assay sen-
itivity by including reference groups; (2) narrowing the range of
ermissible sensitivity; (3) expressing the results in international
nit (IU) of PT activity relative to a common reference; and (4)
stablishing limits basedonapanel of productswithaknownsafety
istory.
In summary, current quality control tests and specifications for
P vaccines are product-specific, and the clinical relevance of this
pproach remains uncertain. An effective potency assay for new
roducts and formulations should be defined, and suitable refer-
nce preparations should be identified. For the current histamine
ensitization test, an upper limit for active residual PT should be
efined and use of a reference preparation should be encouraged.
inally, a specific assay for residual active PT that does not require
se of animals should be identified. The challenge in testing of
P-based combination vaccines still remains.
0.3. A view from the vaccine manufacturers: GlaxoSmithKline
GSK)
For the immunologic evaluation of DTaP combinations and co-
dministrationswithDTaP-basedvaccines, GSK referredback to the
riginalDTaPefficacy trials. The cornerstoneof comparisons among
ombined vaccines to their separately administered licensed coun-
erparts is the evaluation of the antibody responses to PT, FHA and
RN [85]. Noninferiority of the percentage of vaccine responders as
ell as of geometric mean titers forms the basis for the licensure
f new combinations and co-administrations. Reverse cumulative
ntibody distribution curves are also useful for such comparisons.
urther characterizationsofnewDTaPcombinationsbyGSK involve
he evaluation of clinical T-cell responses aswell as preclinical eval-
ations in a mouse lung clearance model [85].
With respect to vaccine composition and protection, the avail-
ble data suggest potent DTwP and DTaP containing PT and
RN induce high levels of protection against whooping cough
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27,28,86,87]. The mechanisms linked to PRN-mediated protection
elate to the observations that PRN expression affects ACT activ-
ty [88] and induces opsonophagocytic antibodies [89]. The DTaP
fficacy trials have been contradictory with regard to the efficacy
f DTaP2 (PT+ FHA without PRN). Initially the efficacy of DTaP2
as reported to be 85% in Senegal, according to WHO criteria, but
his was later corrected to 74% since the original diagnostic crite-
ia were different from other trials [90]. This 74% efficacy of DTaP2
n Senegal probably is similar to the 59% efficacy observed with
nother DTaP2 in Sweden because of the finding that PT immune
esponses inSenegal aremore than1.5 timeshigher than inWestern
urope [91]. In conclusion,DTwPandDTaPwith≥3components are
he preferred options for immunization against whooping cough.
TaP5hasdemonstrated efficacy comparablewithDTaP3, although
t is uncertain if FIM3 is a protective antigen [92]. The duration
f protection with DTwP and DTaP can be estimated at 6 years or
ore [93]. To further control pertussis in newborns, adolescents
nd adults, DTaP booster immunizations can be recommended [8].
0.4. A view from the vaccine manufacturers: sanofi pasteur
Sanofi pasteur has been using immunoassays for B. pertussis –
gG ELISAs for PT, FHA, PRN, and FIM antigens – to support the eval-
ation of vaccine-induced immune responses. The assays used are
ssentially those identified by Manclark et al. [94]. Key reagents
re qualified and standardized, coating antigens are highly purified
nd assessed both by physical chemistry and immunologic meth-
ds to ensure purity, antigenicity, and specificity. Assay reference
era are bridged to international references, and the performance
as demonstrated to remain stable. Control sera are shown to be
pecific and represent suitable ranges across the range of the assay.
ll components are qualified, with performance panels of sera to
nsure consistency. All assays have been fully validated by preci-
ion (inter- and intralaboratory), accuracy (using spike recovery),
pecificity (assessing matrix effects and performing competition
tudies), linearity/dilutability, limit of detection (LOD), limit of
uantitation (LOQ), and robustness.
From the perspective of a vaccine manufacturer such as sanofi
asteur, issues and concerns for the task of global standardization
hould focus on critical reagents and data reduction methods. For
oating antigens, consideration needs to be given to the impact
f antigen source as well as the criteria for quality, and consump-
ion rate. For references, most laboratories have been forced to
evelop internal references that are bridged to international stan-
ards; guidance is needed on how best to select these internal
eferences and the sustainability of international references to sup-
ort frequent calibrations. Similarly, guidance is needed on the best
haracteristics for controls and implementation of quality control
ndassayacceptancecriteria. Finally, fordata reduction, guidance is
eeded to establishwhichdata reduction systems aremost suitable
n today’s laboratory.
1. Harmonization of serologic assays for B. pertussis.
roup discussion and action items
Chairpersons: Freyja Lynn, BS (National Institute of Allergy
nd Infectious Diseases, National Institutes of Health, Bethesda,
aryland, US) and Annette Morris, BS, BEd (Canadian Center for
accinology, Dalhousie University, Nova Scotia, Canada)
To achieve harmonization of assays for the clinical diagnosis
f pertussis and evaluation of immunity postvaccination, several
ssues will have to be addressed. First, consensus on methodolo-
ies, assay validation, and analysis of results is required to facilitate
omparisons among data generated in different laboratories. The
equirements for adiagnostic assaywill likelydiffer in someaspects
R27 (2009) 803–814 811
rom assays used to perform postvaccination immunity evalua-
ion. Stability of assay results over time will be dependent on
he consistent availability of appropriately characterized reagents
nd materials. Studies are required to determine the effect on
ssay results of different sources and lots of antigen, conjugate
nd other reagents. A proficiency panel of human sera is vital to
armonization of methods between laboratories, although creat-
ng a panel with sufficient volume for worldwide use will be a
hallenge. A reference laboratory or a series of connected refer-
nce laboratories will be essential as resources for methodology,
hange control and management and evaluation of the proficiency
anel. Finally, a repository for the distribution of standardized
aterials, such as antigens, conjugates, and reference materials,
ill be crucial for standardization and harmonization of B. pertussis
ssays.
A steering committee should be established for the purpose
f identifying and prioritizing the steps toward harmonization,
ncluding identification of resources required for implementa-
ion. If harmonization is to be accomplished, it must be a global
ffort with the collaboration of many research, government and
orporate organizations. The WHO is currently evaluating a collab-
rative study of proposed international reference preparations for
uman pertussis antiserum. If these are shown to be acceptable,
he availability of international reference material will be valuable
or promoting harmonization. Additionally, the collaborative study
ata, available mid-2008, will provide information on comparabil-
ty of results in participating laboratories and will help point to
here priorities should be focused.
Actionable items to accomplish standardization and harmo-
ization of B. pertussis immunoassays identified during group
iscussion included the following: (1) identify a group that will
rganize, prepare, maintain, and distribute a common pertussis
erformance serumproficiency panel that can be used to help labo-
atories to develop their assays and monitor stability; (2) assemble
working group to assist with the details of the panel; (3) encour-
ge the development and identification of one or more reference
aboratories that can serve as an anchor and resource for other
aboratories; (4) focus on key reagents such as reference and con-
rol sera; (5) define a performance-based assay method that can
erve as a reference point for evaluating laboratory differences; (6)
evelop guidance on quality of other reagents, e.g., PT and other
ntigens, and methods to demonstrate their suitability; (7) estab-
ish an international working group to harmonize the criteria to
valuate the results obtained on reference and proficiency panel
era; (8) create an inventory to determine the amount of appro-
riate and well-characterized sera that are available globally to
e used as bridging reagents for vaccine licensure; and (9) seek
pecific guidance from regulatory authorities regarding the expec-
ations and requirements for the licensure of new multicomponent
ertussis vaccines.
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